Core Viewpoint - The company, Gilead Sciences-B (01672.HK), announced its participation in the 2025 Obesity Week in Atlanta, Georgia, where it will present multiple obesity treatment candidates, including ASC30, ASC31, and ASC47 combination therapy [1] Group 1: Presentation Details - The company will report on the oral GLP-1 receptor biased small molecule agonist ASC30 in a 28-day multiple ascending dose study [1] - An Ib phase study on ASC30, a monthly subcutaneous injection small molecule GLP-1 receptor agonist in obese subjects, will also be presented [1] - The combination of GLP-1 receptor/GLP receptor agonist peptides ASC31 and ASC47 showed a relative weight loss improvement of 119.6% compared to tirzepatide in diet-induced obese mice [1] Group 2: Company Statements - The founder, chairman, and CEO of the company expressed excitement about the ongoing progress of their small molecule and peptide obesity pipeline, highlighting a strong commitment to developing differentiated obesity treatment solutions [1]
歌礼制药-B(01672.HK)：将携ASC30口服片、ASC30注射剂和ASC31与ASC47联合疗法的研究结果亮相2025年肥胖周